PubRank

W J Storkus

Author PubWeight™ 79.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995 3.67
2 NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol 1987 3.06
3 Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996 2.92
4 Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996 2.69
5 Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994 2.68
6 Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody. Infect Immun 1990 1.70
7 Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996 1.64
8 Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994 1.64
9 Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996 1.32
10 NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res 2000 1.26
11 Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995 1.26
12 Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995 1.25
13 Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med 1995 1.24
14 Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol 2000 1.20
15 Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A 2000 1.19
16 Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000 1.19
17 FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997 1.12
18 Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 1996 1.05
19 Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol 1998 1.04
20 Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997 1.04
21 Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999 1.03
22 Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 2000 1.02
23 gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer 2001 1.02
24 Killer dendritic cells: mechanisms of action and therapeutic implications for cancer. Cell Death Differ 2007 1.02
25 Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol 1994 1.00
26 Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther 1994 1.00
27 Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine. Mol Immunol 2008 0.98
28 Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995 0.98
29 Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci U S A 1999 0.98
30 Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci 1996 0.98
31 HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. J Immunol 1999 0.95
32 Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J Immunol 1994 0.94
33 Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother 1998 0.94
34 DNA immunization targeting the skin: molecular control of adaptive immunity. J Invest Dermatol 1998 0.91
35 Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother Emphasis Tumor Immunol 1993 0.91
36 Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 2001 0.91
37 Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol 1999 0.90
38 Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 2001 0.90
39 Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur J Immunol 1997 0.90
40 Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996 0.90
41 Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther 2009 0.89
42 New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 1996 0.88
43 Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther 1999 0.88
44 Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA. Nat Immun 1995 0.87
45 Multiple melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes. J Immunol 1996 0.87
46 IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther 2006 0.87
47 EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells. Am J Transplant 2007 0.87
48 Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol 1999 0.87
49 Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity. Gene Ther 2007 0.86
50 Interferon-alpha gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Ther 1997 0.86
51 Dendritic cell based therapy of cancer. Adv Exp Med Biol 1997 0.86
52 B cell sensitivity to natural killing: correlation with target cell stage of differentiation and state of activation. J Immunol 1986 0.86
53 IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 1995 0.85
54 Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Clin Exp Immunol 2007 0.84
55 Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther 2011 0.82
56 Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells. J Immunol 2000 0.82
57 IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann N Y Acad Sci 1996 0.81
58 Identification of Meth A sarcoma-derived class I major histocompatibility complex-associated peptides recognized by a specific CD8+ cytotoxic T lymphocyte. Cancer Res 1995 0.81
59 Gene-based strategies for the immunotherapy of cancer. J Mol Med (Berl) 1997 0.81
60 Oxygen-reactive metabolites are not detected at the effector-target interface during natural killing. J Leukoc Biol 1986 0.81
61 Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis. Clin Cancer Res 1996 0.81
62 Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 1999 0.80
63 Quantitation and sorting of vitally stained natural killer cell-target cell conjugates by dual beam flow cytometry. Cytometry 1986 0.79
64 Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells. Cancer Gene Ther 2013 0.79
65 Murine models of cancer cytokine gene therapy using interleukin-12. Ann N Y Acad Sci 1996 0.78
66 TCR usage in CTLs recognizing melanoma/melanocyte antigens. Immunol Today 1995 0.78
67 DNA vaccines targeting dendritic cells for the immunotherapy of cancer. Adv Exp Med Biol 1998 0.77
68 Use of autologous dendritic cells loaded with apoptotic LCL for ex vivo generation of specific CTL from the PBMC of EBV(-) individuals. Transplant Proc 2001 0.77
69 Human thymic epithelial cells inhibit IL-15- and IL-2-driven differentiation of NK cells from the early human thymic progenitors. J Immunol 2001 0.76
70 Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage. Cancer J Sci Am 2006 0.76
71 Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. Eur J Immunol 1996 0.76
72 Giving DNA vaccines a helping hand. Nat Med 1998 0.75
73 Development of dendritic cell-based genetic vaccines for cancer. Adv Exp Med Biol 1997 0.75
74 The immunology of DNA vaccines. Methods Mol Med 2000 0.75